Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma
- Compare the effect of adjuvant hepatic intra-arterial iodine I 131 lipiodol vs
observation in terms of rate of recurrence and overall survival of patients with
curatively resected hepatocellular carcinoma.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Within 4-6 weeks after prior resection, patients receive adjuvant hepatic
intra-arterial iodine I 131 lipiodol once.
- Arm II: After prior resection, patients undergo observation. Patients are followed
monthly for 1 year and then every 3 months thereafter.
PROJECTED ACCRUAL: A minimum of 300 patients (150 per treatment arm) will be accrued for
Allocation: Randomized, Primary Purpose: Treatment
London L. Ooi Peng Jin, MD
National Cancer Centre, Singapore
United States: Federal Government